BRAF and melanoma: In SKMEL5 cell lines and MM099 short-term melanoma cell culture and 1205Lu xenografts in mice, targeting DDR with imatinib was shown to increase the efficacy of BRAF inhibitors, counteract collagen remodeling, and delay melanoma recurrence [235].